The objective of this proposal is to image the responses of tumors to new chemotherapeutic drugs in animals, while they are undergoing experimental treatment, and to develop new noninvasive imaging methods to assess the molecular/biochemical effects on the pathways these drugs were designed to inhibit, at doses that are tolerable in animals. This proposal describes a pilot program for the achievement of these goals. We will specifically use animal models for breast and prostate cancer to study the antitumor effects of a drug derived from geldanamycin; namely, 17-allylarninogeldanamycin (17-AAG). We will use PET scanning with [18F]-fluorodeoxyglucose (FDG) and [124I]-iododeoxyuridine (IUdR) to image the tumor response to the drug, and [18F]-dihydrotestosterone (FDHT) to image changes in the androgen receptor. Effects on glucose utilization and tumor proliferation will be correlated with changes in the physical size and pathological markers of tumor response; in prostate xenografts (LNCaP), androgen receptor imaging with FDHT will also be performed. In collaboration with Project 1 of this P-50 application, we will attempt to image loss of HER2-SHC interactions and inhibition of Ras-dependent signaling by the drug. These results will be correlated with direct measurements of HER2, steroid receptor and Raf degradation and downregulation of D cyclin expression in pathologic specimens. A second objective is to evaluate the use of imaging in determining drug response and to develop methodologies to image inhibition of specific signaling pathways. If successful, these techniques will become an integral component of the preclinical development of the drugs we are studying. It is important to note that the animal imaging studies in Aims 1 and 3 of this proposal are complementary to the imaging studies that will be performed on patients with advanced metastatic prostate cancer, as proposed in Project 4 of this P-50 application. In both projects, one objective is to obtain metabolic (phenotypic) images in order to assess and better understand the progression and response of cancer to new molecular-based treatment modalities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA086438-01
Application #
6401552
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2000-06-01
Project End
2005-05-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Dunphy, Mark P S; Harding, James J; Venneti, Sriram et al. (2018) In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 287:667-675
Serganova, Inna; Moroz, Ekaterina; Cohen, Ivan et al. (2017) Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Mol Ther Oncolytics 4:41-54
Graham, Nicholas A; Minasyan, Aspram; Lomova, Anastasia et al. (2017) Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 13:914
Lu, Shaohua; Tan, Kay See; Kadota, Kyuichi et al. (2017) Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. J Thorac Oncol 12:223-234
Pankov, Dmitry; Sjöström, Ludvig; Kalidindi, Teja et al. (2017) In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget 8:65917-65931
Kim, Kwanghee; Zhang, Hanwen; La Rosa, Stephen et al. (2017) Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy. Clin Cancer Res 23:3343-3351
Shrestha, Liza; Patel, Hardik J; Kang, Yanlong et al. (2017) Copper Mediated Coupling of 2-(Piperazine)-pyrimidine Iodides with Aryl Thiols using Cu(I)Thiophene-2-carboxylate. Tetrahedron Lett 58:4525-4531
Lee, Jason T; Zhang, Hanwen; Moroz, Maxim A et al. (2017) Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging. Mol Imaging Biol 19:100-108
Weidenauer, Lorenz; Wang, Tai; Joshi, Suhasini et al. (2017) Proteomic interrogation of HSP90 and insights for medical research. Expert Rev Proteomics 14:1105-1117

Showing the most recent 10 out of 191 publications